Form 4: Danimer Scientific CFO Granted Stock Appreciation Rights and Performance Stock Award

Michael A. Hajost, CFO of Danimer Scientific, received stock appreciation rights and a performance stock award under the company's 2020 Long-Term Incentive Plan.

Summary

• Michael A. Hajost, the Chief Financial Officer of Danimer Scientific, Inc., was granted stock appreciation rights (SARs) and a performance stock award (PSA) on April 3, 2024.
• The SARs cover 327,869 shares of the company's Class A common stock and vest in three tranches between April 3, 2025, and April 4, 2027.
• The PSA consists of 188,679 performance shares, which will vest based on the company's achievement of Total PHA Revenue and Adjusted EBITDA targets by December 31, 2026.
• 50% of the performance shares will vest based on Total PHA Revenue, with full vesting at $157 million and partial vesting at $135 million.
• The other 50% will vest based on Adjusted EBITDA, with full vesting at $22.3 million and partial vesting at $17.2 million.
• Pro-rata vesting will occur for amounts between the threshold and full vesting targets for both metrics.
• The PSA will expire on the earlier of April 3, 2027, or the Reporting Person's Termination Date.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance. The vesting criteria are challenging but achievable, suggesting a positive outlook.

Positives

• The granting of SARs and PSAs aligns the CFO's interests with the company's long-term performance.
• The vesting criteria for the PSA are tied to specific revenue and profitability targets, incentivizing growth and efficiency.
• The long-term incentive plan is designed to retain key executives.

Risks

• The vesting of the PSA is dependent on the company achieving specific financial targets, which may not be met.
• The value of the SARs is subject to the company's stock price performance, which can be volatile.

Future Outlook

The vesting of the performance stock award is contingent upon the company achieving specific Total PHA Revenue and Adjusted EBITDA targets by the end of 2026.

Industry Context

Incentive plans using stock appreciation rights and performance-based awards are common in the industry to align executive compensation with company performance and shareholder value.

Comparison to Industry Standards

• Many companies in the materials science and sustainable packaging sectors use similar long-term incentive plans.
• For example, Novozymes and Corbion, both competitors in the bio-based materials space, utilize a mix of stock options, restricted stock units, and performance-based bonuses to incentivize their executives.
• The specific targets for revenue and EBITDA are tailored to Danimer Scientific's growth strategy and financial projections.

Stakeholder Impact

• Shareholders: The incentive plan aims to align management's interests with shareholder value creation.
• Employees: The plan can motivate employees by linking executive compensation to company performance.
• Management: The plan provides a long-term incentive for executives to drive growth and profitability.

Next Steps

• Monitor the company's progress towards achieving the Total PHA Revenue and Adjusted EBITDA targets by December 31, 2026.
• Track the vesting of the stock appreciation rights as they become exercisable.

Key Dates

Keywords

Danimer Scientific, Stock Appreciation Rights, Performance Stock Award, Incentive Plan, CFO, DNMR, PHA Revenue, Adjusted EBITDA, Vesting